Ceftriaxone-Loaded Polymeric Microneedles, Dressings, and Microfibers for Wound Treatment

Ceftriaxone-Loaded Polymeric Microneedles, Dressings, and Microfibers for Wound Treatment

The objective of this study was to create polymeric dressings, microfibers, and microneedles (MN) loaded with ceftriaxone, using PMVA (Poly (Methyl vinyl ether-alt-maleic acid), Kollicoat 100P, and Kollicoat Protect as polymers to treat diabetic wounds and accelerate their recovery. These formulatio...

Full description

Saved in:
Bibliographic Details
Published in:Polymers Vol. 15; no. 12; p. 2610
Main Authors: Serrano-Castañeda, Pablo, Ochoa Loyo, Miguel Alejandro, Tinoco Hernández, Cristian Ezequiel, Anaya-Ortega, Brian Miguel, Guadarrama-Escobar, Omar Rodrigo, Anguiano-Almazán, Ericka, Rodríguez-Pérez, Betsabé, Peña-Juárez, Ma Concepción, Vázquez-Durán, Alma, Méndez-Albores, Abraham, Rodríguez-Cruz, Isabel Marlen, Morales-Florido, Miriam Isabel, Escobar-Chávez, José Juan
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01-06-2023
MDPI
Subjects:
Bacterial infections
Care and treatment
Ceftriaxone
Ceftriaxone sodium
Diabetes
Diabetic foot
Diffusion cells
dressings
Foot diseases
Health aspects
In vivo methods and tests
Ingredients
Kollicoat® Protect
Maleic acid
Microfibers
microneedles
Needles
Tear strength
Time lag
Vinyl ethers
Water loss
Wound healing
wound treatment
Wounds and injuries
Mexico
United States > US
ceftriaxone
dressings
wound treatment
Kollicoat® MAE 100P
Kollicoat® Protect
microneedles
microfibers
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to create polymeric dressings, microfibers, and microneedles (MN) loaded with ceftriaxone, using PMVA (Poly (Methyl vinyl ether-alt-maleic acid), Kollicoat 100P, and Kollicoat Protect as polymers to treat diabetic wounds and accelerate their recovery. These formulations were optimized through a series of experiments and were subsequently subjected to physicochemical tests. The results of the characterization of the dressings, microfibers, and microneedles (PMVA and 100P) were, respectively, a bioadhesion of 281.34, 720, 720, 2487, and 510.5 gf; a post-humectation bioadhesion of 186.34, 831.5, 2380, and 630.5 gf, tear strength of 2200, 1233, 1562, and 385 gf, erythema of 358, 8.4, 227, and 188; transepidermal water loss (TEWL) of 2.6, 4.7, 1.9, and 5.2 g/h·m ; hydration of 76.1, 89.9, 73.5, and 83.5%; pH of 4.85, 5.40, 5.85, and 4.85; and drug release (Peppas kinetics release) of n: 0.53, n: 0.62, n: 0.62, and n: 0.66). In vitro studies were performed on Franz-type diffusion cells and indicated flux of 57.1, 145.4, 718.7, and 2.7 µg/cm ; permeation coefficient (Kp) of 13.2, 19.56, 42, and 0.00015 cm /h; and time lag (t ) of 6.29, 17.61, 27. 49, and 22.3 h, respectively, in wounded skin. There was no passage of ceftriaxone from dressings and microfibers to healthy skin, but that was not the case for PMVA/100P and Kollicoat 100P microneedles, which exhibited flux of 194 and 0.4 µg/cm , Kp of 11.3 and 0.00002 cm /h, and t of 5.2 and 9.7 h, respectively. The healing time of the formulations in vivo (tests carried out using diabetic Wistar rats) was under 14 days. In summary, polymeric dressings, microfibers, and microneedles loaded with ceftriaxone were developed. These formulations have the potential to address the challenges associated with chronic wounds, such as diabetic foot, improving the outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2073-4360
2073-4360
DOI:10.3390/polym15122610